Anuradha Chakravarthy, MD

home / authors / anuradha-chakravarthy-md

Articles

Weekly Irinotecan and Concurrent Radiation Therapy for Stage III Unresectable NSCLC

Hak Choy, MD;Anuradha Chakravarthy, MD;Russell Devore Iii, MD;Madan Jagasia, MD;Kenneth R. Hande, MD;John R. Roberts, MD;David H. Johnson, MD;Furhan Yunus, MD

July 2nd 2000

In preclinical studies, the topoisomerase I inhibitor irinotecan (Camptosar, CPT-11) has demonstrated activity as a radiosensitizer, probably due to its ability to inhibit potentially lethal radiation damage repair. We conducted a

The Role of Radiation, With or Without Chemotherapy, in the Management of NSCLC

Anuradha Chakravarthy, MD;Hak Choy, MD;David Johnson, MD

October 1st 1999

Lung cancer is the leading cause of cancer death in the United States. Surgery is the treatment of choice for early stage patients. Despite radical surgery, patients with early stage lung cancer remain at risk for recurrence. The